Figure 4: Effect of the chemical PKCβ blocker ([3-(1-(3-Imidazol-1-ylpropyl)- 1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione]) on calcium uptake in intestinal cells suspension. Another series of experiments were done with the same procedure as described in Figure 3 to produce the following conditions: (1) controls (open circle) (2) 300 pM 1,25(OH)2D3 (closed circles) (3) controls in the presence of the PKCβ blocker (open triangles) (4) 300 pM 1,25(OH)2D3 in the presence of the PKCβ blocker (closed triangles). At T = 1, 3, 5, 7, and 10 min, 100 ml samples were pipetted into 900 ml of ice-cold GBSS. Cell samples were centrifuged (1,000 x g, 5 min, 4°C), supernatants decanted and pellets analyzed for radioactivity and protein. Specific radioactivity (cpm/μg protein) was calculated and then values obtained for the treated phase were normalized to average basal phase. Data are presented as mean treated/average basal ratios ± SEM. (aa,bb,cc P < 0.01 and aaa,bbb,dddP < 0.001, relative to controls, 1,25(OH)2D3 and controls plus PKCβ blockers, respectively).